(Yicai Global) Jan. 30 -- China's Food and Drug Administration (CFDA) is reviewing chimeric antigen receptor-T (CAR T) drugs which Galaxy Biomedical Investment Co. jointly developed as immunocellular therapies used to treat cancers, the company, which develops biopharmaceuticals, announced yesterday.
The Center for Drug Evaluation (CDE) under the CFDA will prioritize the review of Galaxy Biomedical's CAR-T drug, the firm said, citing a CDE announcement issued yesterday.
CAR-T cells are genetically modified T cells that target specific objects. Because of their ability to attack tumors, CAR-T therapies are very effective in treating tumors, especially blood tumors. Last year, the US Food and Drug Administration approved two CAR-T drugs for treating blood tumors, meaning CAR-T therapies have since been adopted in practice.
Galaxy Biomedical [SHE:000806] was one of China's first companies to develop CAR-T cell immunotherapies. The company's shares rose to CNY9.3 (USD1.5) from CNY9.2 in trading yesterday. The National Key Laboratory of Biotherapy under Sichuan University is its major partner.
Several other Chinese firms have submitted applications to conduct clinical trials on CAR-T therapies since the fourth quarter of last year. The review of the application by Galaxy Biomedical and Sichuan University is in a later stage than those of other companies, per public information.